EXCLUSIVE: Invesco bets $50m initially to fix clinical trials and reshape pipelines
This article was originally published in Scrip
In a move that could rewrite the clinical trial handbook and rejuvenate drug product pipelines, one of the premier investors in blue chip pharma firms has placed a $50 million two-way bet on a private company that uses social media to make running clinical trials up to 75% cheaper. Invesco Perpetual, which has significant holdings in GSK, AstraZeneca, Pfizer, Amgen and Merck among others, has now invested $50 million in DrugDev, an interactive network and data sharing platform for trial doctors. DrugDev will use Invesco's money both to acquire companies and build internal clinical trial technology capabilities.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.